Curanex Pharmaceuticals Inc. Announces Closing of its Initial Public Offering

Company Overview - Curanex Pharmaceuticals Inc. is a developmental stage pharmaceutical company based in Jericho, New York, focused on discovering and developing botanical drugs for inflammatory diseases [5] - The company's lead candidate, Phyto-N, is a botanical extract with proven anti-inflammatory properties, validated in animal models for six inflammatory diseases, primarily targeting moderate to severe ulcerative colitis [5][6] Initial Public Offering (IPO) Details - Curanex announced the closing of its IPO, offering 3,750,000 shares of common stock at a price of $4.00 per share, resulting in gross proceeds of $15 million [1] - The shares began trading on the Nasdaq Capital Market under the ticker symbol "CURX" on August 26, 2025 [1] - Underwriters were granted an option to purchase up to 562,500 additional shares within 45 days from the closing of the Offering [1] Underwriters and Legal Counsel - Dominari Securities LLC served as the lead underwriter, with Pacific Century Securities LLC and Revere Securities LLC as co-underwriters [2] - The Crone Law Group, P.C. acted as counsel to the company, while Sichenzia Ross Ference Carmel LLP served as lead counsel to the underwriters [2] Regulatory Filings - A registration statement on Form S-1 was filed with the SEC and declared effective on August 12, 2025, with the Offering made only by means of a prospectus [3]